Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma

NCT01835145 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01835145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01835145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2013
Completion date
November 1, 2019
Enrollment
47 (actual)
Sites
228

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent uveal melanoma, stage iii uveal melanoma ajcc v7, stage iiia uveal melanoma ajcc v7, stage iiib uveal melanoma ajcc v7, stage iiic uveal melanoma ajcc v7, stage iv uveal melanoma ajcc v7